Skip to main content

Oriahnn FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 27, 2021.

FDA Approved: Yes (First approved May 29, 2020)
Brand name: Oriahnn
Generic name: elagolix/estradiol/norethindrone acetate and elagolix
Dosage form: Capsules
Company: AbbVie Inc.
Treatment for: Uterine Leiomyomata

Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist, estrogen and progestin co-formulation indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

Development timeline for Oriahnn

May 29, 2020Approval FDA Approves Oriahnn (elagolix/estradiol/norethindrone acetate and elagolix) for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-Menopausal Women

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.